We previously developed peptides that bind to G protein βγ subunits and selectively block interactions between βγ subunits and a subset of effectors in vitro (Scott et al. EMBO J. 20,(767)(768)(769)(770)(771)(772)(773)(774)(775)(776). Here, we created cell permeating versions of some of these peptides by N terminal modification with either myristate or the cell permeation sequence from HIV tat. The 
Summary
We previously developed peptides that bind to G protein βγ subunits and selectively block interactions between βγ subunits and a subset of effectors in vitro (Scott et al. EMBO J. 20, (767) (768) (769) (770) (771) (772) (773) (774) (775) (776) . Here, we created cell permeating versions of some of these peptides by N terminal modification with either myristate or the cell permeation sequence from HIV tat. The myristoylated βγ binding peptide (mSIRK) applied to primary rat arterial smooth muscle cells caused rapid activation of ERK1/2 in the absence of an agonist. This activation did not occur if the peptide lacked a myristate at the N terminus, if the peptide had a single point mutation to eliminate βγ-subunit binding, or if the cells stably expressed the C terminus of βARK1. An HIV tat modified peptide (tatSIRK), and a myristoylated version of a second peptide (mSCAR) that binds to the same site on βγ subunits as mSIRK, also caused ERK activation. mSIRK also stimulated Jun N-terminal kinase (JNK) phosphorylation, p38 MAP kinase phosphorylation, phospholipase C activity and caused Ca 2+ release from internal stores. When tested with purified G protein subunits in vitro, SIRK promoted α subunit dissociation from βγ subunits without stimulating nucleotide exchange. These data suggest a novel mechanism by which selective βγ-binding peptides can release G protein βγ subunits from heterotrimers to stimulate G protein pathways in cells.
Introduction
G protein βγ subunits released from αβγ heterotrimers, in response to G protein coupled receptor activation, regulate a variety of physiological processes including heart rate, neuronal excitability and neutrophil chemotaxis. This regulation is mediated by interactions between βγ subunits and a variety target molecules ranging from inwardly rectifying potassium channels to soluble enzymes such as phospholipase C (see (1) for a review). βγ subunit-dependent regulation of the majority of its targets is inhibited by theα-GDP subunit. α-GDP is thought to sterically occlude a binding site on βγ subunits shared by all its effectors. Activation of βγ dependent signaling occurs when α-GTP dissociates and uncovers this binding site (2) . On the other hand a number of binding sites for effectors outside the βγ-α subunit interface have been identified by mutagenesis (3) or peptide crosslinking (4) . A model emerging from this analysis predicts βγ subunit effectors may share a common interaction surface at the βγ-α subunit interface but individual effectors also have unique interaction surfaces on βγ that could be targeted pharmacologically.
To probe the nature of common and unique binding sites on βγ subunits we screened random peptide libraries using purified G protein βγ subunits as the target to identify peptide sequences required for binding to various surfaces on βγ (5). Four divergent families of peptides were identified that all bound to a single site on the βγ subunit surface. We hypothesized this interaction surface represented a protein-protein interaction "hot-spot" with the capacity to accommodate a diversity of amino acid sequences. Random peptide library screens often target such protein interaction surfaces (6;7). The peptides inhibited the interaction between βγ subunits and effector molecules such as phospholipase C (PLC) 1 β and PI 3-kinase γ (PI3Kγ).
Interestingly, these peptides did not affect regulation of other effectors such as adenylyl cyclase type I or voltage gated calcium channels, demonstrating selective interference with particular G protein βγ subunit-target interactions. This indicates that the proposed "hot spot" is not a common binding surface for all βγ effectors.
Most inhibitors of G protein βγ subunit-target interactions, such as the C-terminal domain of β adrenergic receptor kinase (βARK1ct), are thought to be universal βγ subunit inhibitors, blocking activation of all downstream target molecules. Thus the βARK1ct has been used extensively in intact cells as a global inhibitor of βγ subunit signaling (8) . The goal of this study was to introduce peptides derived from the phage display screen into intact cells to investigate the consequences of selectively interfering with particular G protein βγ subunit-target interactions in intact cells. To our surprise we found these peptides caused activation of G protein signaling in the absence of receptor activation. We provide evidence for a mechanism where these selective peptides bind to βγ subunits and promote dissociation of α subunits but leave a surface available on βγ subunits for activation of MAP kinase pathways.
Experimental Procedures.
Materials. Peptides were synthesized by Alpha Diagnostics International, purified by HPLC to greater than 90% purity, and the identity of the peptides was confirmed by mass spectrometry analysis. -free HBSS, and Ca 2+ imaging was performed as described previously (10) . Between 6 and 20 cells were followed in each experiment, and all experiments were repeated at least 3 times with similar results. Traces show responses of individual cells. Preparation of biotinylated βγ subunits. The cDNA for rat β1 subunit was subcloned into a baculovirus transfer vector for expression of amino terminal fusions of a biotin acceptor peptide (11) . The biotin acceptor peptide is a stretch of 20 amino acids that is the substrate for the enzyme biotin holoenzyme synthetase (BirA). When a protein fused to the biotin acceptor peptide is coexpressed with BirA the protein becomes biotinylated in vivo at a specific lysine residue in the acceptor peptide sequence. The rat β1 subunit was subcloned by PCR with pfu polymerase (Stratagene) using primers:
Measurements of inositol phosphates (IPs
and cloned into the baculovirus transfer vector PDW464 in frame with the biotin acceptor sequence between the AscI and EcoRI restriction sites to yield MAGGLNDIFEAQKIEWHEDTGGA…β1 sequence, with the lysine residue being the site of biotinylation. Baculovirus was generated via recombination in bacteria as described in the Bacto-Bac system manual (Invitrogen). Biotin-β 1 γ 2 was purified from Sf9 cells using hexahistidine tagged α i1 following previously published procedures (12) . Biotinylation of the purified β subunit was confirmed by SDS-PAGE followed by western blotting with streptavidin linked horseradish peroxidase and detection with chemiluminescence. To confirm that the β subunit was fully biotinylated it was precipitated with streptavidin agarose and greater that 90% of the β subunit was removed from the supernatant by this procedure. 
Results
To investigate the consequence of selectively inhibiting βγ subunit functions in intact cells, we created cell permeating peptides by synthesizing one of our phage display selected peptides, SIRKALNILGYPDYD (SIRK) with myristate (17) at the amino terminus (mSIRK). We tested the ability of this peptide to affect activation of ERK1 and ERK2 in primary cultures of rat arterial smooth muscle (RASM) cells. In these cells it has been shown that ERK1 and ERK2 can be activated by stimulation of G protein-coupled lysophosphatidic acid (LPA) receptors. This activation is blocked by pertussis toxin and by an adenovirus expressing the βARK1ct, implicating G i and βγ subunits in the activation process (18) . For these reasons, we predicted that our cell permeating peptides might block LPA-induced ERK activation. To analyze the specificity of this effect we created a second myristoylated version of this peptide where leucine 9 was changed to alanine (mSIRK(L9A)). We had previously performed alanine scanning mutagenesis of SIRK and found substitution of A for L9 increased the IC 50 of this peptide for blocking βγ-dependent PLC activation by over 100 fold (from 3 µM to 300 µM) phosphorylation. The necessity for myristoylation of the peptide for cellular activity supports the idea that entry of the peptide into the cell is needed to cause ERK activation. To further support the need for intracellular action, we constructed a peptide where the 11 amino acid cell permeation sequence from HIV tat (19) was added to the amino terminal end of SIRK (tatSIRK).
Fluorescein was attached to the amino terminus to monitor cellular uptake. TatSIRK was efficiently taken up into virtually all of cells on the dish as monitored by fluorescence microscopy (not shown). TatSIRK was able to activate ERK1/2 to an extent comparable to mSIRK ( Fig. 1D ) while tatSIRK(L9A) had no effect (data not shown). These cell permeating peptides activated ERK to a greater extent than LPA and to an extent comparable to EGF in this assay paradigm (Fig. 1D ). Together, these data indicate structural requirements in the peptides for βγ binding need to be maintained to observe ERK1/2 activation, and that the peptides need to get inside the cell and are not acting by binding to cell surface receptors. This, in conjunction with the observation that the concentration requirement for ERK1/2 activation correlates with the apparent K d of SIRK for βγ subunits in vitro (5), strongly supports the idea that βγ is the target of the peptides and this targeting is responsible for ERK1/2 activation.
G βγ is the target of the peptides in the intact cell. To further support the idea that βγ subunits are the target of the peptides in intact cells, we tested a peptide with a completely different amino acid sequence from SIRK. The peptide, SCARFFGTPCP (SCAR), was also selected in the phage display screen and we have shown by competition analysis that SCAR peptide binds to βγ subunits in vitro at the same site as SIRK (5). We predicted a myristoylated version of SCAR (mSCAR) should have the same effect as mSIRK on ERK1/2 activation in RASM cells. We have also shown that for SCAR to bind to βγ subunits the cysteine residues must form an intramolecular disulfide bond. If SCAR is reduced with DTT, it is no longer able to bind to βγ in a phage ELISA assay. The results in figure 2A show mSCAR activates ERK1/2, pretreatment with DTT eliminates its ability to activate ERK1/2, while DTT has no effect on the ability of the linear mSIRK to stimulate ERK1/2. These data emphasize that the structure of the peptide binding to βγ subunits is important to observe activation of ERK1/2, not just the peptide sequence.
To provide further evidence G βγ subunits are the target of mSIRK and related peptides, we tested the ability of mSIRK to cause ERK1/2 activation in a RASM cell line stably transfected with the C-terminal region of βARK that sequesters βγ subunits (βARK1ct (Gly 495 -Leu 689 )) (8;9). We hypothesized that mSIRK was binding to βγ but leaving a surface available on βγ to signal to some downstream targets. Based on this hypothesis, we predicted that ERK1/2 activation by mSIRK would be inhibited by the βARK1ct, a general βγ inhibitor that blocks signaling of βγ to most if not all effectors. The data in figure 2B demonstrate that in cells expressing βARK1ct, activation of ERK1/2 was almost completely inhibited compared to the control RASM cells. This indicates that βγ subunit signaling is the target of these peptides.
Cell type specificity of ERK activation by mSIRK. All of the experiments described so far used rat arterial smooth muscle cells. To examine the generality of this response mSIRK was tested in a variety of cell lines. The results in figure 3A show that the effect of mSIRK is dependent on the cell type. RASM and Rat2 cells show dramatic activation of ERK1/2 by mSIRK while other smooth muscle cells, such as ddtMF2 cells show very little, but some response. These differences could be due to a variety of factors. One possibility is that the myristoylated peptide is only able to enter certain cell types. We therefore tested the effects of tatSIRK on HEK293 and Cos7 cells. Similar to mSIRK, tatSIRK had only small effects on activation of ERK1/2 (not shown). We were able to monitor the uptake of tatSIRK into these cells with a fluorescein label and confirmed that this peptide did indeed enter the cells. This indicates that the cell type specific responses are not due to differential uptake of the peptides and differences in the endogenous MAP kinase signaling systems may be responsible, i.e., in some cell types βγ dependent MAP kinase activation is stronger than others.
Activation of ERK1/2 requires src but not EGF receptor transactivation or calcium release from internal stores. We used a variety of pharmacological inhibitors to examine the pathway involved in the response to mSIRK. As expected a MEK inhibitor PD98059 was able to completely block the effect of the peptide (not shown). PP2, a specific src family tyrosine kinase inhibitor, was able to completely block mSIRK mediated activation of ERK1/2 (Fig. 3B) . Src is thought to be involved in βγ-mediated activation of ERK1/2 by GPCRs, consistent with a pathway involving βγ subunits (20) . The involvement of EGF receptor transactivation was tested using a specific inhibitor of the EGF receptor, AG1478. This inhibitor completely blocked the ability of the EGF receptor to activate ERK1/2 but had no effect on ERK1/2 activation by m-SIRK (Fig. 3B) . Thapsigargin treatment, which almost completely emptied the intracellular calcium stores (data not shown and figure 4B), was unable to block the effect of mSIRK indicating release of calcium from intracellular stores is not responsible for ERK1/2 activation (Fig. 3C) . Finally, treatment with pertussis toxin did not block the effect of mSIRK ( (Fig 4C) . Since PP2 blocks src activation and the subsequent pathway leading to ERK1/2 activation, the IP 3 release is not an indirect consequence of activation of this pathway.
mSIRK activation of many G protein dependent pathways suggests mSIRK is binding to βγ subunits and somehow promoting release of βγ subunits, leaving a surface available to signal to downstream pathways. A potential problem with this hypothesis is that SIRK blocks PLC stimulation by βγ in vitro (5) and thus should block the βγ surface required to signal to PLC. Nucleotide exchange can also be assayed by measuring the steady state rate of GTP hydrolysis on the α subunit. In this assay, the rate of hydrolysis is limited by the rate of exchange of GDP for GTP. The amphipathic peptide mastoparan stimulated the rate of hydrolysis of γ[ 32 P]-GTP by G o while mSIRK did not (figure 5C), indicating that mSIRK cannot stimulate GDP dissociation. Also shown in figure 5D is that mastoparan has virtually no effect on ERK activation in RASM cells while mSIRK stimulates significant ERK activation.
To determine if SIRK could stimulate dissociation of α from βγ in the absence of nucleotide exchange, we assayed the binding of α subunits to biotinylated βγ subunits bound to streptavidin agarose beads. G protein α subunits (10 nM) were incubated with 10 nM biotinylated βγ subunits bound to streptavidin agarose beads and incubated with mSIRK or AlF 4 -for 20 minutes. The beads were centrifuged, the supernatant removed and the bound α subunits estimated by quantitative western blotting ( Figure 6A ). At 10 and 30 µM mSIRK the amount of α subunit bound to βγ subunits was significantly lower than in the absence of added mSIRK.
A drawback of the pulldown assay is the high concentrations of α and βγ required to detect binding and the relatively crude nature of the quantitation. At 10 nM, each of the subunits was used at concentrations significantly above the estimated K d for α-βγ interactions of about 1 nM. A more quantitative assay to measure α-βγ interactions at very low subunit concentrations has recently been developed that uses flow cytometry to assess the amount of fluorescent α subunit bound to biotinylated βγ subunits immobilized on beads (15;16) . In this assay, where SIRK and FITC labeled α i (F-α i ) are simultaneously mixed with βγ subunits, there was a dose dependent decrease in the amount of α subunit bound to βγ subunits while SIRK(L9A) had no effect ( Figure 6B ). At 10 µM SIRK, F-α i bound to βγ is reduced by 75% compared to only 25% in the pulldown assay. This probably reflects that the G protein subunit concentration in this assay is near the K d for the α-βγ interaction making it easier to observe a decrease in binding.
A possible mechanism for the increase in α-βγ dissociation might involve direct competition between the peptide and the α subunit for the α subunit-binding site on βγ subunits.
In this model, the peptide would increase net subunit separation by preventing rebinding of α-GDP subunits after dissociation. This process would be inherently slow because it would depend on spontaneous dissociation of tightly bound α-GDP from βγ. A second possibility is the peptide promotes dissociation of α from βγ subunits by a mechanism that does not involve direct competition. These two possibilities can be distinguished by measuring the α subunit dissociation rate. If the peptide simply competes for the α subunit-binding site on βγ subunits then the dissociation rate should be equivalent to the intrinsic α subunit dissociation rate. If the rate of α subunit dissociation in the presence of peptide is greater than the intrinsic dissociation rate, it would suggest the peptide can promote G protein subunit dissociation. We measured the intrinsic rate of F-α i dissociation from βγ by adding a 50 fold excess of unlabeled myristoylated α i subunit at time 0 and measuring the amount of F-α i bound to βγ at various times using flow cytometry (Fig. 7A) . The intrinsic off rate was slow, with a k off between 0.05 and 0.08 min -1 (t ½ ~ 9-14 min) in four separate experiments. These data are similar to previously published results (0.047 min -1 ) with this assay, and consistent with the low apparent K d for α-βγ interactions (15) .
The rate of α dissociation from βγ was also measured at various times after addition of SIRK.
The initial rate of dissociation was rapid, with the majority of the dissociation occurring within 2 min (t ½ ~1 min or less). The dissociation with peptide was in two phases, an initial rapid phase followed by a slower dissociation with a rate constant similar to the intrinsic α subunit dissociation rate. The extent of initial rapid dissociation by peptide was always at least 75% of the total dissociation that occurred after α subunit alone was added for at least 1h.
To examine the initial dissociation phase in more detail, data were collected in real time using the continuous data collection mode of the flow cytometer. Over the time course of 300 s, the peptide treated samples had a significantly higher rate of dissociation compared to the intrinsic dissociation rate measured with unlabeled α i as the sole competitor ( figure 7B ). The peptide dependent dissociation rate ranged from 5 to 14 fold faster than the intrinsic dissociation rate in 7 separate experiments. The variation resulted primarily from difficulty in getting an accurate quantitative estimate of the intrinsic k off over the short time course of the measurement.
Overall, these data indicate SIRK can promote rapid dissociation of α from βγ subunits without promoting nucleotide exchange on the α subunit.
Discussion

Activation of ERK1/2 by βγ inhibitory peptides
There is extensive evidence in the literature suggesting free βγ subunits released from G i heterotrimers, upon α subunit activation and dissociation, can initiate activation of multiple MAP kinase pathways (22;23) . We have done extensive characterization of our peptide system to show the effects we observe are specifically due to interactions of our peptides with βγ homology to the SIRK peptide, but binds to the same surface on βγ subunits, also caused activation of ERK1/2. The fact that activation of ERK1/2 is blocked by the src inhibitor PP2
indicates our βγ "inhibitory peptides" are acting though a pathway similar to that which has been previously described as being involved in MAP kinase activation by βγ (20) . Finally, if the peptide is tested in RASM cells that express the βARK1ct, the effect on ERK1/2 activation is greatly attenuated. All of these data indicate the G protein signaling system, and the βγ subunits specifically, are the targets for binding these peptides in cells, resulting in the activation of signal transduction that has been presented.
Hot spot binding peptides promote α-βγ dissociation.
We had previously characterized SIRK and other phage display-selected βγ binding peptides in vitro and demonstrated they could selectively interfere with the activation of some effectors by βγ subunits. We also postulated they interact with a protein-protein interaction "hot spot" on the surface of βγ subunits because all the selected peptides, with diverse sequence characteristics, bound to the same site on βγ subunits. Here we demonstrate these effectorselective βγ blocking peptides initiate activation of certain G-βγ dependent signaling pathways in intact cells in a receptor-independent fashion. We show the peptides can promote dissociation of α subunits from βγ subunits without inducing nucleotide exchange. In order to explain the ability of these peptides to activate cellular signaling, they must bind to βγ subunits to decrease the binding of α to βγ, but leave the surface on βγ subunits required to activate MAP kinase pathways unoccupied. A defining characteristic of these peptides is they block interactions with some downstream targets but not others (5) . This unique characteristic of these βγ-blocking peptides makes this proposed mechanism possible. The precise molecular target of βγ subunits in ERK1/2 activation has not been defined, so we cannot test the effects of these peptides on this particular interaction directly.
If these peptides promote βγ release, then why is there cell type specificity to ERK activation as shown in figure 3A ? We believe this reflects the different degrees to which free βγ can activate ERK in different cell types. RASM cells have previously been demonstrated to have a robust βγ dependent activation of ERK (18) . We suspect that βγ is probably released by peptide treatment in all the cells tested, but they may have different levels of the signaling molecules necessary for robust βγ stimulated ERK1/2 activation.
It is becoming increasingly clear, particularly through the identification of AGS proteins (24) , there are multiple mechanisms for G protein activation that do not depend on receptordependent nucleotide exchange. The data we present here indicate binding to a previously postulated "hot spot" on βγ subunits can promote subunit dissociation in vitro and activate G protein βγ subunit dependent pathways in cells. This suggests a potential mechanism for regulating G protein βγ subunit dependent signaling by proteins (either effectors or other types of proteins such as RGS proteins) interacting directly with the peptide binding "hot spot". A protein with properties similar to our peptides is a protein designated AGS2 (activator of G protein signaling 2) that was found in a yeast screen for receptor-independent mechanisms for G protein activation. AGS2 was shown to bind to βγ subunits, but not α subunits, and could activate the pheromone response pathway in yeast. AGS2 is identical to Tctex 1, a component of the cytoplasmic motor protein dynein. A possible interpretation of the ability to Tctex 1 to cause separation of α from βγ is that Tctex1 is a βγ subunit effector that can cause separation of α from βγ but leaves surfaces available on βγ to interact with the yeast signaling machinery.
Still remaining to be resolved is how SIRK peptide promotes subunit dissociation. One hypothesis is the peptide causes a conformational change in the βγ subunit that promotes subunit dissociation. Generally it is not thought that the βγ subunits undergo significant conformational changes because the conformations of βγ crystallized with and without α subunits are very similar (25) (26) (27) (28) . On the other hand the structure of βγ crystallized in the presence of phosducin shows significant conformational alteration (29;30) . Interestingly, a peptide derived from phosducin that apparently binds outside of the α subunit-binding site alters α-βγ subunit interactions suggesting that binding to βγ can transmit information to the α subunit interface (31) . The peptides we derived from phage display have similarity to a region of phosducin that binds outside of the α subunit interface. We previously postulated that the site on βγ subunits where this region of phosducin binds is where our peptide binds. If true, it suggests a truly novel mechanism for G protein activation involving conformational alteration of βγ.
An alternative hypothesis is since α-βγ interactions involve two parts of α (i.e. switch regions and N-terminus) (26;27) , the slow dissociation of α and βγ may depend on the requirement for simultaneous breaking of these two contacts. If each contact were dynamic, mSIRK peptide binding to βγ (for example at the site where βγ contacts the N-terminus) would leave only one contact, which would generate a complex with a lower stability and lifetime. In contrast, addition of excess α subunit could only prevent reassociation following full release of α from βγ due to steric interference between the incoming and outgoing α subunits. Identification and characterization of the peptide-binding site is critical to determination of this mechanism. 1 Abbreviations used: PLC, Phospholipase C; PI3K, Phosphoinositide 3-kinase; RGS, regulator of G proteins signaling; RASM, rat arterial smooth muscle; JNK, Jun N-terminal kinase; LPA, lysophosphatidic acid; EGF, epidermal growth factor βARKct, C-terminus of β-adrenergic receptor kinase; DTT, dithiothreitol; C 12 E 10 , polyoxyethylene 10-lauryl ether.
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